Self-balancing Personal Exoskeleton for SCI (WINY)

This personal exoskeleton, developed by Wandercraft as a new version of the Atalante X, offers a novel hands-free and self-balancing design, aiming at enhancing stability and mobility for users in daily activities.

The study features an interventional, prospective, single-group, and open-label design, conducted over 3 to 4 weeks in a US investigation site. It aims to enroll up to 12 SCI users and their 12 companions, resulting in 12 SCI user-companion pairs.

Over the course of nine to ten scheduled visits, participants undergo a sequence of procedures, beginning with screening and device fitting. This is followed by five training sessions which conclude with an evaluation to issue a competency certificate to confirm the ability to use the device across all its "basic skills". Additionally, two sessions are dedicated to evaluating the exoskeleton's effectiveness outcomes, complemented by an extra practice session. Each visit lasts an average of 1.5 hours.

SCI user inclusion Criteria:

• Any gender, age 18 years or older;
• Motor complete or incomplete SCI with lesions at or above T6;
• ≥ 6 months post SCI;
• Able and willing to attend 9 to 10 visits1 to the center, including sessions of training and assessments of one-to-three hours duration;
• Able to read, understand, and provide informed consent;
• Living in the US and speaks English.

SCI user exclusion Criteria:

• Diagnosis of neurological injury other than SCI;
• Progressive condition that would be expected to result in changing neurological status;
• Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician;
• Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking;
• Knee (proximal tibia and/or distal femur) BMD <0.60 gm/cm2;
• Total hip BMD T-scores < -3.5;
• Fragility, minimal trauma, or low impact fracture of the lower extremity since SCI;
• Untreatable severe spasticity judged to be contraindicated by the site physician;
• Untreated/uncontrolled hypertension, as judged to be contraindicated by the site physician;
• Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and/or fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician;
• Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton;
• Morphological contraindications to the use of the device;
• Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools;
• Unable to effectively operate the device with a hand-control interface, due to functional and/or cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the hand control interface.
• Improper fitting in the device;
• Psychopathology documentation in the medical record that may conflict with study objectives;
• Pregnancy or women who plan to become pregnant during the study period;
• Concurrent participation in another interventional trial;
• History of uncontrolled autonomic dysreflexia;
• Presence colostomy and/or urostomy;
• Ventilator use at the time of the exoskeleton use;

Companion inclusion Criteria:

• Any gender, age 18 years or older;
• Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user;
• Able to read, understand and provide informed consent;
• Living in the US and speaks English.

Companion exclusion Criteria:

• Inability to communicate with an assistant due to cognitive and language disorders;
• Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments;
• Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance/fall;
• Insufficient availability to complete the study;
• Concurrent participation in another interventional trial.